BET bromodomain inhibition cooperates with PD-1 blockade to facilitate antitumor response in Kras-mutant non-small cell lung cancer

KRAS mutation is present in approximately 30% of human lung adenocarcinomas. Although recent advances in targeted therapy have shown great promise, effective targeting of KRAS remains elusive, and concurrent alterations in tumor suppressors render KRAS-mutant tumors even more resistant to existing t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Immunol Res
Main Authors: Adeegbe, Dennis O., Liu, Shengwu, Hattersley, Maureen M., Bowden, Michaela, Zhou, Chensheng W., Li, Shuai, Vlahos, Raven, Grondine, Michael, Dolgalev, Igor, Ivanova, Elena V., Quinn, Max M., Gao, Peng, Hammerman, Peter S., Bradner, James E., Diehl, J. Alan, Rustgi, Anil K., Bass, Adam J., Tsirigos, Aristotelis, Freeman, Gordon J., Chen, Huawei, Wong, Kwok-Kin
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6170698/
https://ncbi.nlm.nih.gov/pubmed/30087114
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-18-0077
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados